Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia

International Journal of Antimicrobial Agents

Volumn 36, Issue 4, 2010, Pages 387-389

  Korakianitis, Ioannis ^a   Mirtsou, Vasiliki ^a   Gougoudi, Evangelia ^a   Raftogiannis, Maria ^b   Giamarellos Bourboulis, Evangelos J ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COTRIMOXAZOLE; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SCREENING; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HUMAN; INCUBATION TEMPERATURE; INCUBATION TIME; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; STENOTROPHOMONAS MALTOPHILIA; TIME FACTORS;

EID: 77955917610     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.006     Document Type: Letter

References (8)

1. Aisenberg G., Rolston K.V., Dickey B.F., Kontoyiannis D.P., Raad I.I., Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007, 26:13-20.
2. Lai C.H., Chi C.Y., Chen H.P., Chen T.L., Lai C.J., Fung C.P., et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004, 37:350-358.
3. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 2004, 57:1-7.
4. Spencer R.C. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995, 30(Suppl.):453-464.
5. Giamarellos-Bourboulis E.J., Karnesis L., Galani I., Giamarellou H. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2002, 46:3997-3999.
6. Plachouras D., Giamarellos-Bourboulis E.J., Kantepozidis N., Baziaka F., Karagianni V., Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007, 57:419-422.
7. Falagas M.E., Valkimadi P.E., Huang Y.T., Matthaiou D.K., Hsueh P.R. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008, 62:889-894.
8. Hermsen E.D., Hovde L.B., Sprandel K.A., Rodvold K.A., Rotschafer J.C. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2005, 49:685-689.